CoChat

Muscarinic acetylcholine receptor 3 localized to primary endothelial cilia regulates blood pressure and cognition

Open access

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Abstract

We previously demonstrated that the inability of primary endothelial cilia to sense fluid shear stress can lead to nitric oxide (NO) deficiency and cause hypertension (HTN). Decreased biosynthesis of NO contributes to cerebral amyloid angiopathy in Alzheimer's disease (AD) patients through increased deposition of amyloid beta (Aβ). However, the molecular mechanisms underlying the pathogenesis of HTN and AD are incompletely understood. The objective of this study was to examine the pathophysiological roles of vascular primary cilia and muscarinic acetylcholine receptor 3 (CHRM3) in HTN and AD. We discovered, for the first time, that CHRM3 was localized to primary cilia of endothelial and cerebrovascular cells, and that CHRM3 expression was downregulated in cilialess cells. Moreover, CHRM3 activation enhanced cilia length and sensory function in terms of eNOS activation. To further examine the role of vascular CHRM3 in vivo, we showed that endothelial CHRM3 knockout was associated with increased BP and attenuated acetylcholine-mediated vascular relaxation. In addition, endothelial CHRM3 knockout resulted in altered fear behavior. This demonstrates the physiological significance of endothelial CHRM3 signaling and primary cilia-derived NO production as an important mechanism in the control of BP and cognition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-025-87212-3

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CHRM3 expression and localization to primary cilia. (a) Immunofluorescence staining with antibodies against acetylated α-tubulin and CHRM3 in wildtype and Tg737Orpk/Orpk endothelial cells. Images were captured at 60X magnification. (b) Ciliary localization of CHRM3 was confirmed by quantifying the number of ciliated cells in which CHRM3 is localized to primary cilia, to ciliary base, or to other cellular compartments (Other). CHRM3 localizations were examined from 3 preparations in each group, and at least 100–200 cilia were randomly selected in each preparation. (c) Western blot analysis to examine CHRM3 expression in wildtype and Tg737Orpk/Orpk endothelial cells. N = 6 cell preparations. Means are ± SEM. Unpaired two-tailed t-test, *P < 0.0296 denotes significant difference between CHRM3 expression in wildtype and Tg737Orpk/Orpk endothelial cells. t = 2.536, df = 10. Confocal immunofluorescence analysis of CHRM3 localization in HBEC cells stained with antibodies against (d) CHRM3 (green) and acetylated α-tubulin (red), e. Arl13b (green) and PIP2 (red), and f. CHRM3 (green) and PIP2 (red). g. Confocal immunofluorescence analysis of CHRM3 localization in HBEC cells transfected with expression vector containing Chrm3 gene fused to GFP (CHRM3-GFP) and stained with antibodies against acetylated α-tubulin (red) and GFP was imaged in green. (h) Cilia length and (i) ciliation frequency were quantified in wildtype cells transfected with CHRM3-GFP. N = 3 cell preparations with at least 50–100 cilia/preparation. Means are ± SEM. Unpaired two-tailed t-test, *P < 0.0028 denotes significant difference between cilia length in wildtype-CHRM3 and corresponding values in wildtype non-transfected cells. t = 3.009, df = 322. Images were captured at 60X and 40X magnifications. Scale bar, 5 μm.
Fig. 1 CHRM3 expression and localization to primary cilia. (a) Immunofluorescence staining with antibodies against acetylated α-tubulin and CHRM3 in wildtype and Tg737Orpk/Orpk endothelial cells. Images were captured at 60X magnification. (b) Ciliary localization of CHRM3 was confirmed by quantifying the number of ciliated cells in which CHRM3 is localized to primary cilia, to ciliary base, or to other cellular compartments (Other). CHRM3 localizations were examined from 3 preparations in each group, and at least 100–200 cilia were randomly selected in each preparation. (c) Western blot analysis to examine CHRM3 expression in wildtype and Tg737Orpk/Orpk endothelial cells. N = 6 cell preparations. Means are ± SEM. Unpaired two-tailed t-test, *P < 0.0296 denotes significant difference between CHRM3 expression in wildtype and Tg737Orpk/Orpk endothelial cells. t = 2.536, df = 10. Confocal immunofluorescence analysis of CHRM3 localization in HBEC cells stained with antibodies against (d) CHRM3 (green) and acetylated α-tubulin (red), e. Arl13b (green) and PIP2 (red), and f. CHRM3 (green) and PIP2 (red). g. Confocal immunofluorescence analysis of CHRM3 localization in HBEC cells transfected with expression vector containing Chrm3 gene fused to GFP (CHRM3-GFP) and stained with antibodies against acetylated α-tubulin (red) and GFP was imaged in green. (h) Cilia length and (i) ciliation frequency were quantified in wildtype cells transfected with CHRM3-GFP. N = 3 cell preparations with at least 50–100 cilia/preparation. Means are ± SEM. Unpaired two-tailed t-test, *P < 0.0028 denotes significant difference between cilia length in wildtype-CHRM3 and corresponding values in wildtype non-transfected cells. t = 3.009, df = 322. Images were captured at 60X and 40X magnifications. Scale bar, 5 μm.CC BY-NC-ND · PubMed Central
Fig. 2 Selective CHRM3 modulation alters cilia length and ciliation frequency. Immunofluorescence using antibodies against acetylated α-tubulin (green) and pericentrin (red) was used to examine cilia length and ciliation frequency in response to 50–500 μM cevimeline treatment in (a i–iii) Wildtype (N = 1795, F(4,1791) = 140.7, P < 0.001), and (b i–iii) Tg737Orpk/Orpk (N = 1385, F(4,1381) = 74.21, P < 0.001) endothelial cells, or in response to 0.5–10 μM p-F–hexahydro-sila-difenidol, HHSiD treatment in (c i–iii) Wildtype (N = 1243, F(5,1238) = 14.95, P < 0.001) endothelial cells. 1-Way ANOVA with Tukey’s posthoc test, comparisons were made to control vehicle-treated cells. *P < 0.05, **P < 0.01, and ***P < 0.001. Individual data points represent cilia length measurements made from 4 preparations in each group, and cilia were randomly selected in each preparation. N represents number of cilia measured in each group. Images were captured at 60X magnification. Scale bar represents 5 μm. Means are ± SEM. Ciliation frequency is presented as whisker box with average value in the middle and minimum and maximum values as error bars.
Fig. 2 Selective CHRM3 modulation alters cilia length and ciliation frequency. Immunofluorescence using antibodies against acetylated α-tubulin (green) and pericentrin (red) was used to examine cilia length and ciliation frequency in response to 50–500 μM cevimeline treatment in (a i–iii) Wildtype (N = 1795, F(4,1791) = 140.7, P < 0.001), and (b i–iii) Tg737Orpk/Orpk (N = 1385, F(4,1381) = 74.21, P < 0.001) endothelial cells, or in response to 0.5–10 μM p-F–hexahydro-sila-difenidol, HHSiD treatment in (c i–iii) Wildtype (N = 1243, F(5,1238) = 14.95, P < 0.001) endothelial cells. 1-Way ANOVA with Tukey’s posthoc test, comparisons were made to control vehicle-treated cells. *P < 0.05, **P < 0.01, and ***P < 0.001. Individual data points represent cilia length measurements made from 4 preparations in each group, and cilia were randomly selected in each preparation. N represents number of cilia measured in each group. Images were captured at 60X magnification. Scale bar represents 5 μm. Means are ± SEM. Ciliation frequency is presented as whisker box with average value in the middle and minimum and maximum values as error bars.CC BY-NC-ND · PubMed Central
Fig. 3 Selective CHRM3 modulation enhanced cilia sensory function. (a–c) Western blot analysis was employed to assay total protein lysates from Wildtype and Tg737Orpk/Orpk endothelial cells for p-eNOS (N = 5–7, F(7,40) = 4.539, P < 0.0008) and eNOS (N = 3, F(7,16) = 0.1802, P < 0.9857) expression following treatment with cevimeline (Cev. 500 µM) under static or fluid shear stress conditions. GAPDH was used as a loading control. Bar graph represents averaged fold change in protein expression relative to wildtype control vehicle-treated cells. Means are ± SEM. N represents cell preparations. 1-Way ANOVA with Dunnett’s posthoc test. *P < 0.05, **P < 0.01, and ***P < 0.001.
Fig. 3 Selective CHRM3 modulation enhanced cilia sensory function. (a–c) Western blot analysis was employed to assay total protein lysates from Wildtype and Tg737Orpk/Orpk endothelial cells for p-eNOS (N = 5–7, F(7,40) = 4.539, P < 0.0008) and eNOS (N = 3, F(7,16) = 0.1802, P < 0.9857) expression following treatment with cevimeline (Cev. 500 µM) under static or fluid shear stress conditions. GAPDH was used as a loading control. Bar graph represents averaged fold change in protein expression relative to wildtype control vehicle-treated cells. Means are ± SEM. N represents cell preparations. 1-Way ANOVA with Dunnett’s posthoc test. *P < 0.05, **P < 0.01, and ***P < 0.001.CC BY-NC-ND · PubMed Central
Fig. 4 CHRM3 ciliary localization is associated with cilia length. (a) In wildtype cells, immunostaining using antibodies against acetylated α-tubulin and CHRM3 was used to examine (i.) cilia length in response to treatment with cevimeline (500 μM) in cells where CHRM3 was localized to the ciliary base, ciliary axoneme, or to “Other” non-ciliary compartments. N = 651 cells, 1-Way ANOVA with Bonferroni’s posthoc test, F(5,646) = 10.75, P < 0.0001 denotes significant difference in cilia length in all groups compared to cilia length where CHRM3 was localized to the ciliary base in vehicle-treated cells; #P < 0.05, ##P < 0.01, and ###P < 0.001denotes significant difference between cilia length in cevimeline-treated compared to all other groups. Individual data points represent cilia length measurements. Means are ± SEM, (ii.) CHRM3 localization frequency (%) to ciliary base, ciliary axoneme, or to “Other” non-ciliary compartments was quantified in response to cevimeline treatment (500 μM). N = 986 cells, unpaired two-tailed t-test, **P < 0.0081, t = 4.890, df = 4 significant difference in CHRM3 localization between cevimeline- and vehicle-treated cells, and (iii.) Immunostaining using antibodies against acetylated α-tubulin (red) and CHRM3 (green) was used to show representative images of CHRM3 localization to the ciliary base and axoneme. (b) In HBEC cells, immunostaining using antibodies against (i.) acetylated α-tubulin and CHRM3, and (ii.) PIP2 and CHRM3 was used to examine CHRM3 and PIP2 localization frequency (%) to ciliary base, axoneme, or to “Other” non-ciliary compartments in response to cevimeline treatment (500 μM). N = 658 cells, unpaired two-tailed t-test, NS non-significant difference in CHRM3 and PIP2 localization between cevimeline- and vehicle-treated (control) cells. None denotes no CHRM3 localization was found. Means are ± SEM.
Fig. 4 CHRM3 ciliary localization is associated with cilia length. (a) In wildtype cells, immunostaining using antibodies against acetylated α-tubulin and CHRM3 was used to examine (i.) cilia length in response to treatment with cevimeline (500 μM) in cells where CHRM3 was localized to the ciliary base, ciliary axoneme, or to “Other” non-ciliary compartments. N = 651 cells, 1-Way ANOVA with Bonferroni’s posthoc test, F(5,646) = 10.75, P < 0.0001 denotes significant difference in cilia length in all groups compared to cilia length where CHRM3 was localized to the ciliary base in vehicle-treated cells; #P < 0.05, ##P < 0.01, and ###P < 0.001denotes significant difference between cilia length in cevimeline-treated compared to all other groups. Individual data points represent cilia length measurements. Means are ± SEM, (ii.) CHRM3 localization frequency (%) to ciliary base, ciliary axoneme, or to “Other” non-ciliary compartments was quantified in response to cevimeline treatment (500 μM). N = 986 cells, unpaired two-tailed t-test, **P < 0.0081, t = 4.890, df = 4 significant difference in CHRM3 localization between cevimeline- and vehicle-treated cells, and (iii.) Immunostaining using antibodies against acetylated α-tubulin (red) and CHRM3 (green) was used to show representative images of CHRM3 localization to the ciliary base and axoneme. (b) In HBEC cells, immunostaining using antibodies against (i.) acetylated α-tubulin and CHRM3, and (ii.) PIP2 and CHRM3 was used to examine CHRM3 and PIP2 localization frequency (%) to ciliary base, axoneme, or to “Other” non-ciliary compartments in response to cevimeline treatment (500 μM). N = 658 cells, unpaired two-tailed t-test, NS non-significant difference in CHRM3 and PIP2 localization between cevimeline- and vehicle-treated (control) cells. None denotes no CHRM3 localization was found. Means are ± SEM.CC BY-NC-ND · PubMed Central
Fig. 5 Endothelial-CHRM3 contribute to high blood pressure. (a) Systolic, (b) Diastolic, and (c) MAP were monitored for three days in Chrm3f/f and VECre:Chrm3f/f male and female mice. (d) Averaged systolic, diastolic, and MAP were analyzed among Chrm3f/f and VECre:Chrm3f/f male and female mice. N = 16 male and female mice per genotype, a-c. repeated measures ANOVA with Bonferroni’s post hoc test, F(1,26) = 16.975, P < 0.001 (Systolic), F(1,26) = 8.774, P < 0.006 (Diastolic), and F(1,26) = 12.941, P < 0.001 (MAP) significantly different from corresponding values in Chrm3f/f mice. Individual data points (a-c) represent average BP measurements per 8 mice per day. Means are ± SEM. d. Unpaired two-tailed t-test, *P < 0.05 denotes significant difference between VECre:Chrm3f/f males and corresponding values in Chrm3f/f males, and *P < 0.05 denotes significant difference between VECre:Chrm3f/f females and corresponding values in Chrm3f/f females. Tail-cuff data points represent the average of approximately 15 BP measurements twice per day for three days per mouse. In a-d, red lines and bars represent females, and blue lines and bars represent males. Triangle signs and dotted bars represent knockout (VECre:Chrm3f/f) mice, and circle signs and clear bars represent control (Chrm3f/f) mice. Individual data points (d) represent average BP measurements per mouse.
Fig. 5 Endothelial-CHRM3 contribute to high blood pressure. (a) Systolic, (b) Diastolic, and (c) MAP were monitored for three days in Chrm3f/f and VECre:Chrm3f/f male and female mice. (d) Averaged systolic, diastolic, and MAP were analyzed among Chrm3f/f and VECre:Chrm3f/f male and female mice. N = 16 male and female mice per genotype, a-c. repeated measures ANOVA with Bonferroni’s post hoc test, F(1,26) = 16.975, P < 0.001 (Systolic), F(1,26) = 8.774, P < 0.006 (Diastolic), and F(1,26) = 12.941, P < 0.001 (MAP) significantly different from corresponding values in Chrm3f/f mice. Individual data points (a-c) represent average BP measurements per 8 mice per day. Means are ± SEM. d. Unpaired two-tailed t-test, *P < 0.05 denotes significant difference between VECre:Chrm3f/f males and corresponding values in Chrm3f/f males, and *P < 0.05 denotes significant difference between VECre:Chrm3f/f females and corresponding values in Chrm3f/f females. Tail-cuff data points represent the average of approximately 15 BP measurements twice per day for three days per mouse. In a-d, red lines and bars represent females, and blue lines and bars represent males. Triangle signs and dotted bars represent knockout (VECre:Chrm3f/f) mice, and circle signs and clear bars represent control (Chrm3f/f) mice. Individual data points (d) represent average BP measurements per mouse.CC BY-NC-ND · PubMed Central
Fig. 6 Endothelial-CHRM3 contribute to ACh-mediated vasodilation. (a) Acetylcholine (ACh), (b) SNP, and (c) SKA-31 dose–response curves were assessed by wire myography in aortic segments preconstricted with phenylephrine (PE, 100 nmol/L) from Chrm3f/f and VECre:Chrm3f/f mice. N = 7–8 male and female mice per genotype, repeated measures ANOVA with Fisher’s LSD post hoc test, *P < 0.05 significantly different from corresponding values in Chrm3f/f mice. Red lines and squares represent knockout and black lines and circles represent control mice. Individual data points represent average aortic relaxation (as % of initial preconstriction) of 7–8 mice. Means are ± SEM.
Fig. 6 Endothelial-CHRM3 contribute to ACh-mediated vasodilation. (a) Acetylcholine (ACh), (b) SNP, and (c) SKA-31 dose–response curves were assessed by wire myography in aortic segments preconstricted with phenylephrine (PE, 100 nmol/L) from Chrm3f/f and VECre:Chrm3f/f mice. N = 7–8 male and female mice per genotype, repeated measures ANOVA with Fisher’s LSD post hoc test, *P < 0.05 significantly different from corresponding values in Chrm3f/f mice. Red lines and squares represent knockout and black lines and circles represent control mice. Individual data points represent average aortic relaxation (as % of initial preconstriction) of 7–8 mice. Means are ± SEM.CC BY-NC-ND · PubMed Central
Fig. 7 Fear behavior in endothelial-CHRM3 knockout and 3xTgAD mice. (a) Schematic diagram of fear conditioning test. Freezing response in the 3–6- and 9–12-month-old Chrm3f/f, VECre:Chrm3f/f, and 3xTgAD mice measured as percent time spent freezing during (b i–ii) Habituation period (average of first 300 s) of Day 1. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 15.19, P < 0.0001 for 3–6-month-old group, and F(2,20) = 7.259, P = 0.0043 for 9–12-month-old group, (c i–iv) Fear acquisition during the first 5 time points of Day 1 and average fear acquisition used as a proxy for learning memory rates between mouse genotypes. Repeated measures ANOVA with Bonferroni’s post hoc test, F(2,29) = 0.8840, P = 0.4240 for 3–6-month-old group, and F(2,19) = 20.75, P < 0.0001 for 9–12-month-old group, (d i,ii) Average fear recall/memory of the first 5 timepoints from Day 2 used as a proxy for fear memory. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 1.067, P = 0.3573 for 3–6-month-old group, and F(2,20) = 0.8737, P = 0.4328 for 9–12-month-old group, (e i,ii) Fear extinction in response to all 30 tones of Days 2 and 3 used as a proxy for extinction learning. Repeated measures ANOVA with Bonferroni’s post hoc test, F(2,26) = 4.017, P = 0.030 for 3–6-month-old group, and F(2,17) = 3.209, P = 0.066 for 9–12-month-old group. #P < 0.022 significantly different from corresponding values in VECre:Chrm3f/f mice, (f i,ii) Fear extinction post hoc analysis representing the average of the last 5 timepoints of Day 3. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 5.501, P = 0.0094 for 3–6-month-old group, and F(2,20) = 3.932, P = 0.0363 for 9–12-month-old group, and (g i,ii) Average fear extinction retention assessed by comparing freezing during the first 5 tones of Day 3 to freezing during the last 5 tones of Day 2. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 0.8604, P = 0.4335 for 3–6-month-old group, and F(2,20) = 0.03907, P = 0.9618 for 9–12-month-old group. N = 8 for VECre:Chrm3f/f and 3xTgAD, and N = 16 for Chrm3f/f male and female mice. Means are ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 significantly different from corresponding values in Chrm3f/f mice and #P < 0.05, ##P < 0.01, and ###P < 0.001 significantly different from corresponding values in VECre:Chrm3f/f mice.
Fig. 7 Fear behavior in endothelial-CHRM3 knockout and 3xTgAD mice. (a) Schematic diagram of fear conditioning test. Freezing response in the 3–6- and 9–12-month-old Chrm3f/f, VECre:Chrm3f/f, and 3xTgAD mice measured as percent time spent freezing during (b i–ii) Habituation period (average of first 300 s) of Day 1. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 15.19, P < 0.0001 for 3–6-month-old group, and F(2,20) = 7.259, P = 0.0043 for 9–12-month-old group, (c i–iv) Fear acquisition during the first 5 time points of Day 1 and average fear acquisition used as a proxy for learning memory rates between mouse genotypes. Repeated measures ANOVA with Bonferroni’s post hoc test, F(2,29) = 0.8840, P = 0.4240 for 3–6-month-old group, and F(2,19) = 20.75, P < 0.0001 for 9–12-month-old group, (d i,ii) Average fear recall/memory of the first 5 timepoints from Day 2 used as a proxy for fear memory. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 1.067, P = 0.3573 for 3–6-month-old group, and F(2,20) = 0.8737, P = 0.4328 for 9–12-month-old group, (e i,ii) Fear extinction in response to all 30 tones of Days 2 and 3 used as a proxy for extinction learning. Repeated measures ANOVA with Bonferroni’s post hoc test, F(2,26) = 4.017, P = 0.030 for 3–6-month-old group, and F(2,17) = 3.209, P = 0.066 for 9–12-month-old group. #P < 0.022 significantly different from corresponding values in VECre:Chrm3f/f mice, (f i,ii) Fear extinction post hoc analysis representing the average of the last 5 timepoints of Day 3. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 5.501, P = 0.0094 for 3–6-month-old group, and F(2,20) = 3.932, P = 0.0363 for 9–12-month-old group, and (g i,ii) Average fear extinction retention assessed by comparing freezing during the first 5 tones of Day 3 to freezing during the last 5 tones of Day 2. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,29) = 0.8604, P = 0.4335 for 3–6-month-old group, and F(2,20) = 0.03907, P = 0.9618 for 9–12-month-old group. N = 8 for VECre:Chrm3f/f and 3xTgAD, and N = 16 for Chrm3f/f male and female mice. Means are ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 significantly different from corresponding values in Chrm3f/f mice and #P < 0.05, ##P < 0.01, and ###P < 0.001 significantly different from corresponding values in VECre:Chrm3f/f mice.CC BY-NC-ND · PubMed Central
Fig. 8 Spatial learning in endothelial-CHRM3 knockout and 3xTgAD mice. (a) Schematic diagram of Barnes maze test in 3–6 and 9–12-month-old Chrm3f/f, VECre:Chrm3f/f and 3xTgAD mice to assess (b i,ii) Average latency per day across the three training days. Repeated measures ANOVA with Bonferroni’s post hoc test, F(2,24) = 1.675, P < 0.208 for 3–6-month-old group, and F(2,17) = 7.563, P < 0.004 for 9–12-month-old group, (c i,ii) Primary latency to enter the escape hole on the fourth day. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,27) = 2.666, P = 0.0546 for the 3–6-month-old group, and F(2,17) = 2.666, P = 0.0797 for 9–12-month-old group, and (d i,ii) Time in each quadrant on the fourth day (as a measure of search strategy). 1-Way ANOVA with Bonferroni’s post hoc test, F(2,27) = 0.1269, P = 0.8814 for the 3–6-month-old group, and F(2,20) = 0.1950, P = 0.8244 for 9–12-month-old group. N = 8 for VECre:Chrm3f/f and 3xTgAD, and N = 16 for Chrm3f/f male and female mice. Means are ± SEM. *P < 0.05, and **P < 0.01 significantly different from corresponding values in Chrm3f/f mice and #P < 0.05, and ##P < 0.01 significantly different from corresponding values in VECre:Chrm3f/f mice.
Fig. 8 Spatial learning in endothelial-CHRM3 knockout and 3xTgAD mice. (a) Schematic diagram of Barnes maze test in 3–6 and 9–12-month-old Chrm3f/f, VECre:Chrm3f/f and 3xTgAD mice to assess (b i,ii) Average latency per day across the three training days. Repeated measures ANOVA with Bonferroni’s post hoc test, F(2,24) = 1.675, P < 0.208 for 3–6-month-old group, and F(2,17) = 7.563, P < 0.004 for 9–12-month-old group, (c i,ii) Primary latency to enter the escape hole on the fourth day. 1-Way ANOVA with Bonferroni’s post hoc test, F(2,27) = 2.666, P = 0.0546 for the 3–6-month-old group, and F(2,17) = 2.666, P = 0.0797 for 9–12-month-old group, and (d i,ii) Time in each quadrant on the fourth day (as a measure of search strategy). 1-Way ANOVA with Bonferroni’s post hoc test, F(2,27) = 0.1269, P = 0.8814 for the 3–6-month-old group, and F(2,20) = 0.1950, P = 0.8244 for 9–12-month-old group. N = 8 for VECre:Chrm3f/f and 3xTgAD, and N = 16 for Chrm3f/f male and female mice. Means are ± SEM. *P < 0.05, and **P < 0.01 significantly different from corresponding values in Chrm3f/f mice and #P < 0.05, and ##P < 0.01 significantly different from corresponding values in VECre:Chrm3f/f mice.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

See all 12

Metadata

Authors
Saternos, H. C., Forero, K. V., Meqdad, M. A., Buqaileh, R., Sunderman, C. L., Gallagher, G., Messer, W. S., Mohieldin, A. M., Mucci, C. A., Kumariya, S., Osman, I. A., Burkett, J. P., & AbouAlaiwi, W. A.
Affiliations
  • University of Colorado Anschutz (US)
  • University of Toledo (US)
  • California Northstate University (US)
Corresponding author
AbouAlaiwi, Wissam A.
Venue
Scientific Reports
Published
2025-01-30
Volume
15
Issue
1
Pages
3745-3745
ISSN
2045-2322 (ISSN-L)
OpenAlex
W4406997932
Cited by
12
References
77
Citations by year
2026: 8 · 2025: 4
FWCI
6.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • NIH (R15HL140523, 3R15HL140523-01S1, 3R15HL140523-01S2, 3R15HL140523-01S3)
  • Alzheimer’s Association (AARGD-NTF-22-972749,)
  • NIA (1R03AG080418-01)
  • American Heart Association (19PRE34430055)
  • American Foundation of Pharmaceutical Education (Gateway to Research Award)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
Keywords
M3 muscarinic receptor, primary cilia, hypertension, blood pressure regulation, Alzheimer's disease, cerebral amyloid angiopathy, nitric oxide, endothelial nitric oxide synthase, fluid shear stress, fear behavior, cognition, cilia length
MeSH terms
Acetylcholine, Alzheimer Disease, Animals, Blood Pressure, Cilia, Cognition, Endothelium, Vascular, Humans, Hypertension, Male, Nitric Oxide, Mice, Knockout, Endothelial Cells, Receptor, Muscarinic M3, Mice, Nitric Oxide Synthase Type III

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Muscarinic acetylcholine receptor 3 localized to primary endothelial cilia regulates blood pressure and cognition. https://app.cochat.ai/papers/10.1038/s41598-025-87212-3
The paper
Saternos, H. C., Forero, K. V., Meqdad, M. A., Buqaileh, R., Sunderman, C. L., Gallagher, G., Messer, W. S., Mohieldin, A. M., Mucci, C. A., Kumariya, S., Osman, I. A., Burkett, J. P., & AbouAlaiwi, W. A. (2025). Muscarinic acetylcholine receptor 3 localized to primary endothelial cilia regulates blood pressure and cognition. Scientific Reports. https://doi.org/10.1038/s41598-025-87212-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.